Addex Therapeutics First Half 2013 Financial Results
(Thomson Reuters ONE) -
Addex Therapeutics /
Addex Therapeutics First Half 2013 Financial Results
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Geneva, Switzerland, 17 September 2013 - Addex Therapeutics (SIX: ADXN), a
leading company pioneering allosteric modulation-based drug discovery and
development announced today its first half 2013 financial results.
CHF' thousands H1 2013 H1 2012 Change
----------------------------------------------------------------------------
Income 142 121 17%
R&D expenses (9 315) (11 667) (20%)
G&A expenses (4 760) (3 336) 43%
---------------------------------------
Total operating loss (13 933) (14 882) (6%)
Finance result, net (4) (9) -
---------------------------------------
Net loss for the period (13 937) (14 891) (6%)
---------------------------------------
Basic and diluted net loss per share (1.61) (1.93) (17%)
Net cash used (cash burn) (10 778) (15 829) (32%)
----------------------------------------------------------------------------
CHF' thousands Jun. 30, 2013 Dec. 31, 2012 Change
----------------------------------------------------------------------------
Cash and cash equivalents 4 479 15 257 (71%)
Shareholders' equity 2 883 16 698 (83%)
Income was CHF0.1 million in the first half of 2013 and 2012 and relates to
grants received from The Michael J. Fox Foundation for Parkinson's Research to
partially fund dipraglurant development in Parkinson's disease levodopa induced
dyskinesia.
Research & Development expenses decreased by 20% to CHF9.3 million in the first
half of 2013 compared to CHF11.6 million in the first half of 2012, mainly due
to our reduced headcount and related activities.
General and Administration expenses increased to CHF4.8 million in the first
half of 2013, compared to CHF3.3 million in the first half of 2012, mainly due
to increased professional fees related to a number of strategic initiatives and
restructuring costs.
Net Loss decreased to CHF13.9 million from CHF14.9 million, and included CHF4.7
million of costs related to the restructuring of the organization that took
place in February and May 2013.
Cash and cash equivalents amounted to CHF4.5 million at 30 June 2013, compared
to CHF15.3 million at the end of 2012. Cash utilization for the first half of
2013 of CHF10.8 million is mainly due to the cash used in operations.
Capital increase subsequent to 30 June 2013 balance sheet date was completed on
8 August 2013 and resulted in CHF3.2 million of gross proceeds.
Outlook: Based on current expectations, full year cash utilization guidance is
CHF15 million and cash runway through end of 2014.
The 2013 half year condensed consolidated interim financial statements are
available at http://www.addextherapeutics.com
About Addex Therapeutics
Addex Therapeutics (www.addextherapeutics.com) is a development stage company
focused on advancing innovative oral small molecules against rare diseases
utilizing its pioneering allosteric modulation-based drug discovery platform.
The Company's two lead products are being investigated in Phase 2 clinical
testing: dipraglurant (an mGlu5 negative allosteric modulator or NAM) is being
developed by Addex to treat Parkinson's disease levodopa-induced dyskinesia (PD-
LID) and rare forms of dystonia; and ADX71149 (mGlu2 positive allosteric
modulator or PAM) is being developed in collaboration with Janssen
Pharmaceuticals, Inc., to treat both schizophrenia and anxiety as seen in
patients suffering from major depressive disorder. Addex also has several
preclinical programs including: GABA-BR positive allosteric modulator (PAM) for
Charcot-Marie-Tooth (type 1a) disease, spasticity in patients with multiple
sclerosis (MS), pain, overactive bladder and other disorders; and mGlu4 PAM for
MS, Parkinson's disease, anxiety and other diseases. Allosteric modulators are
an emerging class of small molecule drugs which have the potential to be more
specific and confer significant therapeutic advantages over conventional
"orthosteric" small molecule or biological drugs. The Company uses its
proprietary discovery platform to target receptors and other proteins that are
recognized as essential for the therapeutic modulation of important diseases
with unmet medical needs.
Tim Dyer
Chief Executive Officer
Addex Therapeutics
+41 22 884 1561
PR(at)addextherapeutics.com
Disclaimer: The foregoing release may contain forward-looking statements that
can be identified by terminology such as "seek", "not pursue", "not approvable",
"continue", "believes", "believe", "will", "remained open to exploring",
"would", "could", or similar expressions, or by express or implied discussions
regarding Addex Therapeutics, formerly known as, Addex Pharmaceuticals, its
business, the potential approval of its products by regulatory authorities, or
regarding potential future revenues from such products. Such forward-looking
statements reflect the current views of Addex Therapeutics regarding future
events, future economic performance or prospects, and, by their very nature,
involve inherent risks and uncertainties, both general and specific, whether
known or unknown, or any other factor that may materially differ from the plans,
objectives, expectations, estimates and intentions expressed or implied in such
forward-looking statements. Such factors may in particular cause actual results
with allosteric modulators of mGlu2, mGlu4, mGlu5, GABA-BR or other therapeutic
targets to be materially different from any future results, performance or
achievements expressed or implied by such statements. There can be no guarantee
that Addex Therapeutics will complete the restructuring and reduction of its
liabilities or any financing nor that allosteric modulators of mGlu2, mGlu4,
mGlu5, GABA-BR or other therapeutics targets will be approved for sale in any
market or by any regulatory authority. Nor can there be any guarantee that
allosteric modulators of mGlu2, mGlu4, mGlu5, GABA-BR or other therapeutic
targets will achieve any particular levels of revenue (if any) in the future. In
particular, management's expectations regarding allosteric modulators of mGlu2,
mGlu4, mGlu5, GABA-BR or other therapeutic targets could be affected by, among
other things, unexpected actions by our partners, unexpected regulatory actions
or delays or government regulation generally; unexpected clinical trial results,
including unexpected new clinical data and unexpected additional analysis of
existing clinical data; competition in general; government, industry and general
public pricing pressures; the company's ability to obtain or maintain patent or
other proprietary intellectual property protection. Should one or more of these
risks or uncertainties materialize, or should underlying assumptions prove
incorrect, actual results may vary materially from those anticipated, believed,
estimated or expected. Addex Therapeutics is providing the information in this
press release as of this date and does not undertake any obligation to update
any forward-looking statements contained in this press release as a result of
new information, future events or otherwise, except as may be required by
applicable laws.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Addex Therapeutics via Thomson Reuters ONE
[HUG#1729556]
Unternehmensinformation / Kurzprofil:
Datum: 17.09.2013 - 07:05 Uhr
Sprache: Deutsch
News-ID 297182
Anzahl Zeichen: 9422
contact information:
Town:
Plan-les-Ouates, Geneva
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 200 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Addex Therapeutics First Half 2013 Financial Results"
steht unter der journalistisch-redaktionellen Verantwortung von
Addex Therapeutics (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
